Abstract
Medulloblastoma (MB) treatment in pediatric patients is an open challenge in clinical oncology. Current treatment protocols are risk-adopted and risk group criteria continuously evolve by increasing data about molecular and biologic mechanisms of MB tumorogenesis. In the current issue it is reviewed modern treatment programs, which became a basis of Russian and International clinical recommendations. It is analyzed treatment results according to regimens of chemotherapy and irradiation, absence or presence of metastases, histologic variant and molecular and biologic tumor features.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have